Stanford University
Showing 14,991-15,000 of 36,182 Results
-
Chi-Chang Kao
Professor of Photon Science and Senior Fellow at the Precourt Institute for Energy
BioChi-Chang Kao works on the development of experimental methods exploiting the unique properties of high-brightness storage rings and X-ray Free Electron Lasers (XFEL), and their applications to materials science. Currently, he is working on using X-ray scattering in combination with high magnetic fields to study high-temperature superconductors, inelastic X-ray scattering study of materials using XFEL, and X-ray study of materials for energy applications.
Kao served as the fifth director of the SLAC National Accelerator Laboratory from November 2012 to February 2023. Prior to that, he served at Brookhaven National Laboratory for nearly 25 years in a variety of positions, including five years as chairperson of the National Synchrotron Light Source (NSLS). He was elected a fellow of the American Physical Society in 2006 and was named a fellow of the American Association for the Advancement of Science in 2010 for his many contributions to resonant elastic and inelastic X-ray scattering techniques and their application to materials physics, as well as for his leadership at the NSLS. -
Ming Jeffrey Kao, PhD, MD
Clinical Associate Professor, Anesthesiology, Perioperative and Pain Medicine
Current Research and Scholarly Interests1. Patient-reported outcomes. Efficient, multi-feature item-response theory (IRT) based computerized adaptive testing (CAT) algorithm using item banks from PROMIS and NIH Toolbox
2. Activity monitoring. Novel analytic framework for physical activity monitoring in the context of pain.
3. Operations research. Multi-variable discrete and continuous optimization for Lean Hospital Management
4. National trends in pain medication prescription -
Peter Kao
Associate Professor of Medicine (Pulmonary and Critical Care Medicine)
Current Research and Scholarly InterestsOur research program has several active projects:
1.) Pulmonary Vascular Disease Simvastatin reversed experimental pulmonary hypertension, and is safe for treatment of patients. Blinded clinical trials of efficacy are in progress.
2.) Lung inflammation and regeneration (stem cells)
3.) Lung surfactant rheology and oxidative stress
4.) Gene regulation by RNA binding proteins, NF45 and NF90 through transcriptional and posttranscriptional mechanisms
